NIOD Debuts at Sephora

NIOD (Non-Invasive Options in Dermal Science), the clinical, ingredient-led sister brand to The Ordinary, announces its debut at Sephora. 

This August, NIOD is making its long-awaited debut in Sephora North America, marking the brand’s largest retail expansion to date and introducing its science-first approach to skin optimization to a significantly broader audience.

NIOD has built a devoted following through evidence-led innovation, iterative formulations, and a philosophy centered on optimizing skin function over time rather than simply treating visible signs of aging. 

Ami Bi, VP of Brand at DICIEM, said:

“Sephora is an ideal partner for NIOD because of our shared commitment to pushing the skincare conversation forward through innovation and education. NIOD was created to challenge conventional approaches to skincare by focusing on the skin as a complex, intelligent system rather than something to be overridden with quick fixes. As consumers become increasingly ingredient-aware and science-literate, the launch increases an opportunity to bring NIOD’s advanced, research-led formulation to a wider audience seeking a more sophisticated and comprehensive long-term approach to skin health.”

Now, with Sephora, the brand is bringing its hero technologies, including Copper Amino Isolate Serum 3 1:1 (CAIS3), Copper Amino Isolate Lipid (CAIL), Fractionated Eye-Contour Concentrate (FECC), and Superoxide Dismutase 3 Enzyme Mist (SDEM3), to consumers at an unprecedented scale.

The launch at Sephora reinforces NIOD’s continued momentum and strategic distribution growth, aligning with consumer demand for high-efficacy skincare. Debuting at Sephora is expected to accelerate NIOD’s broader market adoption across key global beauty markets.